Gilead Sciences Inc Stock Price, News & Analysis

Gilead (NASDAQ: GILD) reported Phase 3 ASCENT-03 results showing Trodelvy reduced the risk of disease progression or death by 38% (HR 0.62; p<0.0001) versus chemotherapy as first-line therapy in metastatic triple-negative breast cancer (TNBC) patients not eligible for PD-1/PD-L1 inhibitors.

Key efficacy: median PFS 9.7 months vs 6.9 months, ORR 48% vs 46%, and median DOR 12.2 months vs 7.2 months. Safety was consistent with prior studies; most frequent grade ≥3 events included neutropenia and diarrhea. Overall survival data were not mature. Results presented at ESMO 2025 and published in NEJM.

Gilead (Nasdaq: GILD) will present new HIV data at EACS 2025 (Oct 15–18) covering prevention and treatment advances.

Key points: twice-yearly lenacapavir for PrEP showed safety with concomitant meds and persistence in PURPOSE studies; a Phase 2 twice-yearly lenacapavir+bNAbs regimen maintained suppression to 52 weeks and is moving to Phase 3; an investigational once-weekly islatravir+lenacapavir oral regimen maintained viral suppression at 96 weeks (88.5% missing=failure; 100% missing=excluded); five-year real-world BICSTaR data show sustained suppression on Biktarvy.

Gilead (NASDAQ: GILD) will present new oncology data at ESMO 2025 (Oct 17–21), including late-breaking Phase 3 ASCENT-03 results showing Trodelvy met its primary endpoint with a highly statistically significant, clinically meaningful improvement in progression-free survival versus chemotherapy in first-line metastatic triple-negative breast cancer (TNBC) for patients not eligible for PD-1/PD-L1 inhibitors.

Gilead and Arcus will present EDGE-Gastric Arm A1 overall survival data: median OS 26.7 months with 50% of patients alive >2 years; immune-mediated TEAEs occurred in 22% and infusion reactions in 7%. Trodelvy regulatory approvals and safety warnings are summarized for investors.

Gilead Sciences (Nasdaq: GILD) will release its third quarter 2025 financial results and guidance on Thursday, October 30, 2025 after market close.

Management will host a webcast at 4:30 p.m. Eastern Time on the same day to discuss results and provide a business update. The live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.

Contact details: investor_relations@gilead.com and Gilead Public Affairs phone numbers provided for additional investor inquiries.

Gilead Sciences (NASDAQ:GILD) has announced a significant $6.5 million commitment in STEM education grants through the Gilead Foundation. The funding includes a $1 million grant to Boys and Girls Clubs of America, $500,000 to San Mateo Foster City Education Foundation, and $5 million to San Francisco State University for their Science and Engineering Innovation Center.

This initiative aims to address the projected shortfall of 1.4 million skilled STEM workers by 2030 in the U.S., with STEM skills expected to be essential for 80% of all jobs by the end of the decade. The investment builds on Gilead's broader commitment to the Bay Area, where the company has awarded over $150 million in grant funding to nearly 250 nonprofit organizations since 2018.

Ensoma, backed by Gilead (NASDAQ:GILD), has secured a $53 million financing round from existing investors to advance its in vivo hematopoietic stem cell (HSC) engineering platform. The funding will primarily support the company's recently initiated Phase 1/2 clinical trial of EN-374 for X-linked chronic granulomatous disease (X-CGD), which is now open for patient enrollment.

The investment syndicate includes notable participants such as Gilead, 5AM Ventures, Gates Foundation, and Viking Global Investors. As part of the investment, Gilead has appointed an executive to Ensoma's board. The company aims to develop one-time, outpatient treatments for serious diseases, with additional focus areas in immuno-oncology and sickle cell disease.

Gilead Sciences (Nasdaq: GILD) has announced a groundbreaking partnership with PEPFAR and the Global Fund to provide lenacapavir, a twice-yearly injectable HIV prevention treatment, to up to 2 million people in low- and lower-middle-income countries over three years.

The company will provide the medication at no profit and has secured royalty-free agreements with six generic manufacturers covering 120 high-incidence countries. By end of 2025, Gilead plans to complete regulatory submissions in 18 countries representing 70% of the HIV burden in the covered region.

The initiative follows lenacapavir's recent U.S. approval (as Yeztugo®), European Commission authorization, and positive EU-M4all opinion. Gilead has submitted for WHO prequalification in August 2025, with expected conclusion by year-end.

Gilead Sciences (NASDAQ:GILD) has launched Choose U™, a global awareness campaign highlighting the experiences of people living with HIV. The initiative, unveiled at the 2025 United States Conference on HIV/AIDS, aims to destigmatize HIV and promote treatment adherence through authentic storytelling.

The campaign emphasizes the U=U (undetectable = untransmittable) movement and features real-world stories from individuals maintaining undetectable viral loads. Currently, only two-thirds of the estimated 40 million people living with HIV globally are virally suppressed. The initial wave includes three individual stories, with more than a dozen additional stories from six countries planned for release through 2026.

Gilead Sciences (NASDAQ:GILD) has broken ground on its new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City, California. The five-story, 180,000 square foot facility is part of the company's planned $32 billion U.S. investment through 2030, projected to generate over $43 billion in economic value.

The state-of-the-art facility will feature AI-enabled systems, autonomous robotics, and real-time digital monitoring, serving as a hub for innovation in biologics development. This expansion, along with two other facilities under construction, is expected to create over 3,000 direct and indirect jobs and strengthen Gilead's biologics capabilities, a key component of its growth strategy across virology, oncology, and inflammation.